人福医药：子公司两款药品获药品注册证书

Core Viewpoint - The company has received regulatory approval for two new pharmaceutical products, indicating a positive development in its product pipeline and potential revenue growth [1] Group 1: Product Approvals - The company's subsidiary, Yichang Renfu Pharmaceutical, has been granted a drug registration certificate for the injection of heavy tartrate de-norepinephrine, which is used for blood pressure control in certain acute hypotensive states [1] - The company's wholly-owned subsidiary, Renfu Puke Pharmaceutical, has received approval for ethyl eicosapentaenoate soft capsules, aimed at reducing triglyceride levels in adult patients with severe hypertriglyceridemia (≥500 mg/dL) in conjunction with dietary control [1]